Sir Michael Rawlins, chairman of the U.K.'s Institute for Health and Clinical Excellence (NICE), observes that NICE has "increased the new drugs available to patients and patients are getting a lot of benefit from it....So we're not saving anybody any money, we’re just making sure the money is well spent."